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Abstract: Importance: The US Department of Health and Human Services (HHS) has proposed to re-
form drug pricing in Medicare Part B, which primarily covers physician-administered drugs and biologic
agents. One HHS proposal would shift coverage of certain drugs from Medicare Part B to Part D, which
is administered by private prescription drug plans. Objective: To estimate the association of changes
of a shift in Medicare Part B to Part D with total drug spending and patient cost-sharing. Design,
Setting, and Participants: Retrospective drug cohort study of the 75 brand-name drugs associated with
the highest Part B expenditures among fee-for-service Medicare beneficiaries in 2016. Main Outcomes
and Measures: Estimated total Medicare spending in Part B and Part D; annual out-of-pocket costs
in Part B and under the standard 2018 Part D benefit; and proportion of drugs in Part D’s protected
drug classes (immunosuppressants for prophylaxis of organ transplant rejection, antidepressants, antipsy-
chotics, anticonvulsants, antiretrovirals, and antineoplastics). Results: At 2018 prices, total Medicare
Part B spending for the 75 brand-name drugs with the highest Part B expenditures was estimated to be
21.6billionannually.Undertheproposedpolicy, totalPartDdrugspendingforthesedrugswasestimatedtorangebetween17.6
billion and 20.1billionafterrebates, correspondingtoa6.9%to18.3%decreaseindrugspendinginPartDcomparedwithPartB 9.5
billion (43.9%) in Part B spending, were in protected Part D classes where plans must cover essentially all
drugs. For 67 drugs with available information, the prices for 65 (97.0%) were a median of 45.8% to 59.7%
lower in comparator high-income countries than Part B drug prices. Median patient cost-sharing in Part B
for all 75 brand-name drugs was 4683(interquartilerange[IQR],1069-9282)peryear.ShiftingPartBdrugstothe2018standar
of − pocketcostsbyamedianof860 (IQR, -3884to496) among Medicare beneficiaries without Medicaid or
Part B supplemental insurance (Medigap). For beneficiaries who would qualify for the low-income subsidy
program in Part D, cost-sharing would be lower in Part D than in Part B for all drugs. For beneficiaries
with Medigap insurance, estimated Part D out-of-pocket costs exceeded average Medigap premium costs
by a median of 1460forthosewithPartDcoverageandbyamedianof1952 for those without Part D cover-
age. Conclusions and Relevance: Although the HHS proposal to shift certain drugs from Medicare Part
B to Part D may reduce total drug spending, it may increase out-of-pocket costs for some Medicare ben-
eficiaries, including those with Medicare supplement insurance. The Department of Health and Human
Services should ensure that the proposed reforms benefit both patients and payers.
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Analysis of ProposedMedicare Part B to Part D Shift
With Associated Changes in Total Spending and Patient
Cost-Sharing for Prescription Drugs
Thomas J. Hwang, AB; Nina Jain, MD, MBA; Julie C. Lauffenburger, PharmD, PhD;
Kerstin N. Vokinger, MD, JD, PhD; Aaron S. Kesselheim, MD, JD, MPH
IMPORTANCE The US Department of Health and Human Services (HHS) has proposed to
reform drug pricing in Medicare Part B, which primarily covers physician-administered drugs
and biologic agents. One HHS proposal would shift coverage of certain drugs fromMedicare
Part B to Part D, which is administered by private prescription drug plans.
OBJECTIVE To estimate the association of changes of a shift in Medicare Part B to Part D
with total drug spending and patient cost-sharing.
DESIGN, SETTING, AND PARTICIPANTS Retrospective drug cohort study of the 75 brand-name
drugs associated with the highest Part B expenditures among fee-for-service Medicare
beneficiaries in 2016.
MAIN OUTCOMES ANDMEASURES Estimated total Medicare spending in Part B and Part D;
annual out-of-pocket costs in Part B and under the standard 2018 Part D benefit; and
proportion of drugs in Part D’s protected drug classes (immunosuppressants for prophylaxis
of organ transplant rejection, antidepressants, antipsychotics, anticonvulsants,
antiretrovirals, and antineoplastics).
RESULTS At 2018 prices, total Medicare Part B spending for the 75 brand-name drugs with
the highest Part B expenditures was estimated to be $21.6 billion annually. Under the
proposed policy, total Part D drug spending for these drugs was estimated to range between
$17.6 billion and $20.1 billion after rebates, corresponding to a 6.9% to 18.3% decrease in
drug spending in Part D compared with Part B. Of the 75 drugs studied, 33 (44.0%) drugs,
accounting for $9.5 billion (43.9%) in Part B spending, were in protected Part D classes where
plans must cover essentially all drugs. For 67 drugs with available information, the prices for
65 (97.0%) were amedian of 45.8% to 59.7% lower in comparator high-income countries
than Part B drug prices. Median patient cost-sharing in Part B for all 75 brand-name drugs was
$4683 (interquartile range [IQR], $1069-$9282) per year. Shifting Part B drugs to the 2018
standard Part D benefit was projected to decrease out-of-pocket costs by amedian of $860
(IQR, −$3884 to $496) amongMedicare beneficiaries without Medicaid or Part B
supplemental insurance (Medigap). For beneficiaries who would qualify for the low-income
subsidy program in Part D, cost-sharing would be lower in Part D than in Part B for all drugs.
For beneficiaries with Medigap insurance, estimated Part D out-of-pocket costs exceeded
averageMedigap premium costs by amedian of $1460 for those with Part D coverage
and by amedian of $1952 for those without Part D coverage.
CONCLUSIONS AND RELEVANCE Although the HHS proposal to shift certain drugs from
Medicare Part B to Part Dmay reduce total drug spending, it may increase out-of-pocket
costs for someMedicare beneficiaries, including those with Medicare supplement insurance.
The Department of Health and Human Services should ensure that the proposed reforms
benefit both patients and payers.
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I
n2016,MedicarePartBspending forprescriptiondrugswas
$29.1 billion,primarily formedicationsadministeredby in-
jection or infusion in physician offices and hospital out-
patient departments.1Between2010 and2016,Medicare Part
B drug spending increased by approximately 9.8% on aver-
age per year, comparedwith an average annual growth rate of
8.2% in Medicare Part D program expenditures.1,2
InMay2018, theUSDepartmentofHealthandHumanSer-
vices (HHS) proposed to shift coverage of certain drugs from
Part B to Medicare Part D.3,4 Both programs cover outpatient
prescriptiondrugsbutpay for themdifferently. InPartB,Medi-
care payments are based on the average sales price, which is
the price paid (net of discounts and rebates) by most private
purchasers, plus a statutory add-on amount. In Part D, pri-
vate insurers administer prescription drug plans for Medi-
care beneficiaries; individual Part D plans (and their phar-
macy benefit managers) negotiate with manufacturers to
determine the amounts they pay for drugs.




effects of the proposed reform on total drug spending and pa-
tients’ out-of-pocket costs for prescription drugs.
Methods
Weobtained Part B drug utilization, patient cost-sharing, and
total spending data from the Centers for Medicare & Medic-
aid Services (CMS) Drug Data files, which cover fee-for-
service claims.6Thesedata files summarizePart Bdrug claims
from physicians, outpatient hospitals, and suppliers, and ex-
clude claims billed using NOC codes (“Not Otherwise Classi-
fied”) (eg, J3490, J3590, or J9999), claims for which Medi-
carewasnot theprimarypayer, andclaimswith total spending
amounts of $0 associated with the drug (see eMethods in the
Supplement).6 The study drug cohort comprised brand-
name drugs associated with the highest Part B expenditures,
defined as brand-name drugs with at least $10million in Part
B spending in 2016 (most recent year of data available). Ge-
nericdrugs,devices, vaccines, bloodproducts andclotting fac-
tors, andcertainbiological productswereexcluded (eMethods
in the Supplement).
TheMedicarePrescriptionDrugBenefitManual states that
Part D plan sponsors must include “all or substantially all”
drugs in the6protected classes in their formularies.7Thepro-
tected classes are immunosuppressants for prophylaxis of or-
gan transplant rejection, antidepressants, antipsychotics, an-
ticonvulsants, antiretrovirals, and antineoplastics. We
examinedhowmanyPartBdrugswould fallunderPartD’spro-
tectedclassesandmaythereforeexperience limitedpricecom-
petitioneven ifmoved intoPartD.8Two investigators (N.J. and
J.C.L.) independently reviewedall approved indications indrug
labelsandthenassignedprotectedclassstatus (interrateragree-
ment, 97.3%).9 Per the Medicare Benefit Manual,7 the inves-
tigators consideredbothnewdrugs (ie, indications at the time
of first US Food and Drug Administration [FDA] approval) as
well as newly approved indications since first approval. Drugs
were categorized as (1) fully protected class—all approved in-
dications were in a protected class (eg, bortezomib indicated
for multiple myeloma and mantle cell lymphoma); (2) par-
tially protected class—at least 1 indication was in a protected
class (eg, rituximab indicated for various cancers), but there
were some indications that were not in a protected class
(eg, rituximab indicated for rheumatoid arthritis); and (3) not
protected class—all approved indications were not in a pro-
tected class (eg, omalizumab indicated for asthmaandchronic
idiopathic urticaria). After independent review, the final clas-
sifications were made by consensus.
Current annual drug costs were priced for Part B using
Medicare’s quarterly ASP (Average Sales Price) Drug Pricing
file10 and for Part D using wholesale acquisition costs, which
were a median 5.0% to 6.8% lower than reported standard
pharmacycostsasof July2018 (eMethods in theSupplement).11
Total drug spending in Part B and Part D was estimated using
current prices for each program and unadjusted utilization
(number of units and beneficiaries) per drug from the latest
Medicare Drug Data files. Since Part B drug costs and spend-
ing estimates already include rebates, we estimated “net,” or
rebate-adjusted, drug spending in Part D after accounting for
manufacturer rebates and the coverage gap discount (manu-
facturers provide a 50% discount on drug costs in the cover-
age gap phase of Part D) (Table 1).12Weobtained Part D rebate
levels fromHHS,8 the 2018MedicareTrusteesReport,2 andan
insurance industry–sponsored analysis of rebates for 5 Part D
plans.13 Based on these, Part D spending was adjusted for re-
bates using an average rebate range of 20.0% to 30.0% for
spending on drugs that were not in a protected class and an
average rebate range of 0% to 10.0% for spending on drugs in
any of the protected classes. Medicare’s estimated reinsur-
ancesubsidyobligation (that is, reinsurancepaymentsbyMedi-
care to Part D plans) was also adjusted for rebates, using the
agency’s allocation methodology14 and a shared rebate frac-
tionof 30.0%to40.0%.15Tovalidate theseestimates, in a sen-
sitivity analysis,wealso assessed total rebate-adjusted spend-
Key Points
Question What are the projected effects of the Department of
Health and Human Services (HHS) proposedMedicare Part B drug
pricing reform on drug spending and out-of-pocket costs?
Findings In this analysis of 75 brand-name drugs with the highest
Part B expenditures in 2016, shifting Medicare Part B drugs to Part
D was estimated to decrease total drug spending by 7% to 18%
after rebates. Under the standard 2018 Part D benefit,
out-of-pocket costs for most drugs were projected to be lower in
Part D among fee-for-service Medicare beneficiaries without
Medicaid or supplemental insurance in Part B and among those
whowould qualify for the low-income subsidy program; however,
out-of-pocket costs were estimated to increase among
beneficiaries with Medicare supplement insurance and among
those currently without Part D coverage.
Meaning Although the HHS proposal may reduce total drug
spending, it could increase out-of-pocket costs for someMedicare
beneficiaries.
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ing using drug-specific rebate levels estimated by SSRHealth
LLC, an investment research firm; SSR’s rebate estimateswere
available for45 (60%)of the75 studieddrugs (eMethods in the
Supplement).16
Foreachdrug in thestudycohort,weprojectedannualout-
of-pocket costs under current drug prices and the standard
2018 Part D benefit (Table 1) as the base case. Ranges in pro-
jected Part D out-of-pocket costs were constructed by vary-
ing the coinsurance from 25.0% (standard) to the maximum
33.0% allowable for specialty drugs (defined by Medicare as
monthly costs exceeding $670),17 and by varying annual out-
of-pocket costs in Part D on drugs other than the Part B agent
from $0 to $1169 (beneficiaries in the top 5% of spending).18
CurrentPartB cost-sharingwasestimatedusing currentprices
and actual cost-sharing amounts (as a percentage of spend-
ing) and annual utilization extracted from theMedicare Drug
Data files. In the primary analysis, differences in out-of-
pocket costs under Part B andPartDwere estimated forMedi-
care beneficiaries without Medicaid or supplemental insur-
ance in Part B.
We descriptively considered possible changes in out-of-
pocket costs for beneficiaries without Medicaid who would
qualify for the low-income subsidy program.19,20 The low-
income subsidy program lowers out-of-pocket drug costs in
Part D for eligible individuals with limited income and re-
sources.Wealsoprojectedout-of-pocketcosts inPartDforben-
eficiarieswithMedicare supplement insurance (Medigap) and
for beneficiaries currently without Part D coverage and who
wouldneed topurchase it.Medigap canbepurchased to cover
coinsurance for Part B (but not Part D) drugs.Weobtainedna-
tional average Medigap premiums from the 2016 Medicare
Supplement Insurance Experience Reports.21
Since the HHS proposal suggested that drugs with lower
prices in other countries couldbeprioritized for the shift from
PartB toPartD,3,5wecompareddrugpricesbetweentheUnited
States and other countries and considered changes in out-of-
pocket costs for theseproducts. In secondary analyses,weex-
aminedsubsetsofdrugs in thestudycohort toalignwithpolicy
scenarios proposed by HHS: (1) drugs with prices exceeding
the median of those in comparator high-income countries
(Germany, Japan, Switzerland, and the United Kingdom); (2)
drugscoveredbybothPartBandPartD;and(3) specialtydrugs.
Descriptive statisticswere calculated using Stata version 12.0
(StataCorp Inc).
Results
The study drug cohort comprised 75 brand-name drugs with
the highest Part B expenditures in 2016, with median annual
spending per drug of $98.4 million (interquartile range
[IQR], $37.9-$268.2 million) (eTable 1 and eFigure 1 in the
Supplement). The 75 drugs accounted for $19.8 billion or
77.0% of the $25.7 billion in 2016 fee-for-service Part B drug
spending reported in the Medicare Drug Data file. The 3 Part
B drugs with the highest associated expenditures were
aflibercept (Eylea; Regeneron Pharmaceuticals Inc) with $2.2
billion in spending in 2016, rituximab (Rituxan; Genentech
Inc) with $1.7 billion, and pegfilgrastim (Neulasta; Amgen
Inc) with $1.4 billion. Thirty-three (44.0%) of the 75 drugs
were determined to be in protected Part D classes, of which
30 were antineoplastic agents, 2 were immunosuppressants
for prophylaxis of organ transplant rejection, and 1 was an
antipsychotic (Table 2).
In an advance notice of proposed rulemaking published
on October 25, 2018, CMS suggested that Part B drug prices
were among the highest in the world and considered directly
reducing expenditures for Part B drugs tomore closely reflect
other countries. Therefore, to assess the magnitude of these
price differences,we compareddrugprices in Part B and com-
parator high-incomecountries. For 67drugswith available in-
formation, 65 (97.0%)hadhigher prices in Part B than theme-
dianofprices in comparatorhigh-incomecountries.AsofMay
2018, drug prices in other high-income countries were a me-
dian of 45.8% to 59.7% lower than those in Part B (Figure).
Table 2. Categorization of the 33 Brand-Name Study Drugs
With Protected Class Status and the Highest Part B Expenditures in 2016
Protected Classa
Drugs, No. (%) (n = 33)
All Indications At Least 1 Indicationb
Antineoplastic 24 (32.0) 6 (8.0)
Immunosuppressant (prophylaxis
of organ transplant rejection)
2 (2.7) 0




a For assignment of protected class, see theMethods section.
bRefers to drugs with at least 1 indication approved by the US Food and Drug
Administration and determined to be in a protected Part D class but that also
had other nonprotected indications.
Table 1. Standard 2018Medicare Part D Prescription Drug Benefit
Standard Benefit Phase Standard Benefit Parameters in 2018
Cost-Sharing, %
Beneficiaries Part D Plans Manufacturers Medicare
Deductible Beneficiaries pay 100% of the drug costs until the $405
deductible threshold
100 0 0 0
Initial coverage Beneficiaries pay 25% coinsurance until an initial coverage limit
of $3750
25 75 0 0
Coverage gap Beneficiaries pay 35% coinsurance for brand-name drugs in the
coverage gap until the catastrophic coverage threshold of
$8417.60 in estimated total covered Part D spending
(or out-of-pocket threshold of $5000)
35 15 50 0
Catastrophic coverage Beneficiaries pay 5% coinsurance for the rest of the year or
$8.35 (for brand-name drugs), whichever is greater
5 15 0 80
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Estimated Part B and Part D Drug Spending
With the Proposed Reforms
With 2018 prices, total estimated Part B spending for all 75
brand-namedrugswas$21.6billion.Under theproposedpolicy,
total PartD spendingwas estimated to range from$17.6billion
to $20.1 billion after rebates and discounts, corresponding to
a 6.9% to 18.3%decrease in total rebate-adjusted spending in
Part D compared with Part B (Table 3). Total rebate-adjusted
drug spendingwas estimated todecrease by 10.6% to 21.8% if
HHSshiftedonly specialtydrugs (definedbyMedicareas those
withmonthly costs exceeding $670) fromPart B to Part D. Re-
peating the primary analysis with drug-specific rebate esti-
mates yielded similar results (eTable 2 in the Supplement).
Medicare’s estimated reinsurance subsidyobligationwas $9.7
billion before rebates and $8.0 billion to $9.0 billion after re-
bates, accounting for 43.6% to 47.8% of total Part D spending
after rebates.
Patient Cost-Sharing
Medianestimatedpatientcost-sharing inPartB forall 75brand-
namedrugswas$4683 (IQR,$1069-$9282)at2018prices.Shift-
ing Part B drugs to the standard 2018 Part D benefit was pro-
jected to decrease out-of-pocket costs by a median of $860
(IQR, −$3884 to $496).Whenvarying coinsurance and spend-
ing assumptions, out-of-pocket costs were estimated to in-
crease by at least 10% for 22 to 29 drugs (29.3%-38.9%), and
decrease by at least 10% for 41 to 50 drugs (54.7%-66.7%)
(Table 4). The threshold annual drug cost, for which cost-
sharing in the standardPartDbenefitwouldbe lower than the
coinsurance in Part B, was $15 869 (eFigure 2 in the Supple-
ment). In secondary analyses, resultswere similar for the sce-
narioswhendrugswithprices exceeding themedianof prices
in comparatorhigh-incomecountriesordrugs coveredbyboth
Part B and Part D were shifted to Part D (Table 4). Out-of-
pocket costs were estimated to increase for fewer drugs (2-9
drugs, 3.6%-16.4%vs22-29drugs,29.3%-38.9%) ifHHSshifted
only specialty drugs to Part D.
We also descriptively assessed cost-sharing for the study
drugs for 3 additional categories of Medicare beneficiaries.
First, for those qualifying for the low-income subsidy pro-
gram(approximately 5%-10%of fee-for-serviceMedicareben-
eficiaries), cost-sharing for brand-name drugswould be $0 to
$8.35, depending on income and resources (eMethods in the
Supplement). Second, the national average annual premium
cost for Medigap insurance was $2216 in 2016. For beneficia-
ries with Medigap insurance, estimated Part D out-of-pocket
costs under the proposed policy exceeded average Medigap
premium costs by a median of $1460 (IQR, $171-$2765). The
out-of-pocket costs inPartDwereestimated tobegreater than
average Medigap premium costs for 47 to 56 drugs (62.7%-
74.7%) and to be lower thanMedigap premium costs for 19 to
28 drugs (25.3%-37.3%).
Finally, 12% of Medicare beneficiaries (or approximately
17%of fee-for-servicebeneficiaries) in 2016hadnoPartD cov-
erage or drug coverage that was less generous than Part D’s
standard benefit.1 The effects of the proposed policy on out-
of-pocket costs would similarly depend on supplemental in-
surance.After accounting for theaverageannualpremiumcost
for Part D prescription drug plans ($492 in 2018),1 themedian
estimated decrease in out-of-pocket costs under the pro-
posedpolicywas$368for thesubsetofbeneficiaries thatwould
needtopurchasePartDcoverageanddonothavePartBsupple-
mental insurance or Medicaid. By contrast, for the subset of
beneficiaries with Medigap but not Part D coverage, esti-
mated Part D out-of-pocket costs exceeded average Medigap
premium costs by a median of $1952.
Discussion
TheHHSproposed reforms seek to expand the role of private-
sector negotiation of Medicare drug prices by shifting cover-
age of certain drugs fromPart B to Part D. Consistentwith the
administration's advance notice of proposed rulemaking, we
found that drug prices in other high-income countries were
substantially lower thanPartBdrugprices.22Weestimated that
the proposed policy shift from Part B to Part D could reduce
total drug spending by 6.9% to 18.3% after accounting for re-
bates and discounts. However, the potential for greater over-
all savings was constrained by the fact that 33 (44.0%) of the
studied brand-name drugs were in protected classes, which
HHS has reported precludes meaningful price negotiation by
Part D plans.8 Furthermore, reinsurance payments by Medi-
careaccounted for roughlyhalfof total estimatedPartDspend-
ing. It is possible that shifting costly brand-name drugs from
Part B to Part D could contribute to the rapid growth inMedi-
care’s reinsuranceofPartDdrugcosts.Between2010and2016,
Medicare’s reinsurance spending increased by an average of
21.2% per year, and reinsurance payments became the single
largest component of Part D spending in 2014.1,2 Since Medi-
carepays80%ofdrugcosts in thecatastrophiccoveragephase,
Figure. Comparison of Reported Average Sales Prices forMedicare Part B



























Medicare Part B vs Comparator Countries
Medicare
Part B
Japan Germany Switzerland United
Kingdom
Weighted averageMedian
The ex-factory price for the selected comparator countries is the price exclusive
of sales tax and value-added taxes and adjusted for statutory rebates (but
excludes confidential managed access and performance-based rebates in the
United Kingdom). Illustrated weighted average ratios are weighted at the drug
level by 2016Medicare Part B expenditures. ASP indicates average sales price;
the US ASP = 1. Prices were converted to US dollars at spot exchange rates as of
May 18, 2018 (Swiss franc: 1.002; Euro: 1.179; Pound: 1.347; Yen: 0.009).
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in themedium to long-term, the expanding reinsurance com-
ponentof thePartDbenefitmayattenuate—orpotentiallyeven
eliminate—the incentive for Part D plans to obtain the lowest
drug costs for beneficiaries and the government.23-25
Our analysis also indicates that the proposed policy re-
form could have amaterial impact on patients’ out-of-pocket
costs, with effects varying by drug and patients’ insurance in
addition to Medicare. We estimated that moving drug cover-
age from Part B to Part D could decrease out-of-pocket costs
among patients without supplemental insurance for the ma-
jorityofdrugs,while increasingcost-sharing for29.3%to38.9%
of products (22-29 drugs) (or 3.6%-16.4% if limited to high-
cost specialty drugs; 2-9 drugs). The favorable impact of this
policy shift on cost-sharing would be greatest for beneficia-
rieswhoqualify for the PartD low-income subsidy,which can
eliminate the coinsurance liability based on income and re-
sources.Bycontrast, forpatientswithMedigap insurance, out-
of-pocket costs in Part Dwere estimated to exceed the annual
premiumcosts for supplemental insurance for 62.7% to74.7%
of drugs (47-56 drugs). Out-of-pocket costs would be in-
creased under the proposed policy for beneficiaries withMe-
digap but without Part D coverage.
Limitations
Our study has limitations. First, the study did not account for
possible effects of this proposed reform on insurance premi-
ums or drug utilization. Further actuarial analysis is needed
to more precisely determine the financial impact by stake-
holder (eg, incurred costs for Medicare vs Part D plans). Sec-
ond, the studydidnot includebeneficiaries dually eligible for
Medicare and Medicaid (who would likely have no or mini-
mal change in cost-sharing due to eligibility for the low-
income subsidy in Part D) or those enrolled in employer-
sponsored retiree health plans. TheHHS proposal would also
Table 3. 2018 Total Estimated Drug Spending inMedicare Parts B and Da
Scope of Part B to Part D Shifting Proposal Drugs, No. (%)
Total Estimated Drug Spending, $US Billions
Decrease in Net Spending





Part D Proposed Policy
Before Est Rebatesb After Est Rebatesb
All top-spend Part B drugs in study cohort 75 (100.0) 21.6 24.6 17.6-20.1 6.9-18.3
Secondary analyses
Top-spend Part B drugs with prices exceeding median
of other high-income countriesc
65 (97.0) 20.5 23.3 16.7-19.1 7.2-18.5
Top-spend Part B drugs also covered by Part D 58 (77.3) 16.8 19.8 14.7-16.7 0.7-12.5
Top-spend Part B specialty drugsd 55 (73.3) 17.3 19.3 13.5-15.5 10.6-21.8
Abbreviation: Est, estimated; IQR, interquartile range.
a Represents total estimated drug spending. 2018 drug costs were estimated
using average sales prices (ASP) for Part B and wholesale acquisition costs
(WAC) as of May 18, 2018 for Part D.
bSee theMethods section for rebate estimates; comparison of estimated net
(rebate-adjusted) drug spending refers to Part B drug spending vs estimated
Part D drug spending after accounting for rebates and coverage gap discount.
c Calculated as a proportion of Part B drugs for which foreign prices were
available (n = 67); comparator high-income countries were Germany, Japan,
Switzerland, and United Kingdom; 2 enzyme-replacement therapies
(velaglucerase alfa and imiglucerase) were less expensive in the United States.
dSpecialty drugs are defined byMedicare as those with monthly costs
exceeding $670.
Table 4. Medicare Patient Cost-Sharing in Part B and Under Different Proposed Part D Shift Scenariosa




Median (IQR) Drugs With Estimated Change in OOP Costs, No. (%)b
Part B Current Policy,
Estimated Beneficiary
OOP Cost
Part D Proposed Policy
Projected Beneficiary OOP
Costb Increase ≥10% Decrease ≥10% Change <10%
All top-spend Part B
drugs in study cohort











58 (77.3) 4673 (1223-8329) 2668-3931 (1813-4869) 16-21 (27.6-36.2) 32-40 (55.2-69.0) 2-6 (3.4-10.3)
Top-spend Part B
specialty drugsd
55 (73.3) 5783 (4037-11 655) 3054-4317 (2537-7244) 2-9 (3.6-16.4) 41-50 (74.5-90.9) 3-6 (5.5-10.9)
Abbreviations: IQR, interquartile range; OOP, out-of-pocket.
a Estimated for fee-for-service Medicare beneficiaries without Medicaid
or supplemental insurance in Part B.
bBased on standard Part D drug benefit for 2018. Ranges were constructed by
varying coinsurance from 25.0% to 33.0% (specialty drugs only) and annual
out-of-pocket costs in Part D, on drugs other than the Part B agent, from $0
to $1169 (average out-of-pocket spending on drugs for beneficiaries in the top
5% of spending).
c Calculated as a proportion of Part B drugs for which foreign prices were
available (n = 67); comparator high-income countries were Germany, Japan,
Switzerland, and United Kingdom; 2 enzyme-replacement therapies
(velaglucerase alfa and imiglucerase) were less expensive in the United States.
dSpecialty drugs are defined byMedicare as those with monthly costs
exceeding $670.
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likely only apply to fee-for-service Medicare, which covers
roughly 67% ofMedicare beneficiaries.1 In August 2018, CMS
issued guidance for the Medicare Advantage program that
would parallel the proposed Part B to Part D shift for fee-for-
serviceMedicare.26,27Specifically, theguidancepermitsMedi-
care Advantage plans to apply step therapy to control the uti-
lization of Part B drugs and to cross-manage their Part B and
PartDdrugbenefits (eg, by requiringPartDdrug therapyprior
to covering a Part B drug) for new prescriptions beginning in
January 2019.26 The CMS anticipates that its guidance could
yieldsavingsof 15%to20%forphysician-administereddrugs,27
which is consistentwithour estimate for fee-for-serviceMedi-
care. Finally, while rebate amounts are confidential, we used
current disclosures from HHS and insurers, as well as an in-
dustry database of drug-specific rebate amounts, as the best
available estimates of Part D rebate levels, and our estimates
are in line with those from prior studies.28 Final incurred net
costs in Part Dmay differ from the estimates presented here.
Conclusions
The limitations of the present study are unlikely to substan-
tially change the overall conclusion that significant savings
through rebates offered by manufacturers to Part D plans
and their pharmacy benefit managers would be needed
to justify the potential financial impact of this policy shift
for the Medicare program and for beneficiaries. Recent
analyses by the Congressional Budget Office29 and the White
House’s Office of Management and Budget30 did not quan-
tify the savings to the federal government from this policy.
To achieve long-term cost-savings, additional reforms
may need to be implemented simultaneously, through HHS
rulemaking or legislation. Such reforms might include
value-based pricing,31 flexible formularies that improve the
ability of plans to negotiate lower prices for drugs in pro-
tected classes, and reducing the government’s reinsurance
subsidy in Part D, as has been proposed by the Medicare Pay-
ment Advisory Commission.32 Policy implementation
(eg, through a demonstration project) should be accompa-
nied by rigorous monitoring of patient health outcomes,
access, and quality of care. In the interim, while the poten-
tially offsetting effect of reforms on premiums would need
to be assessed, HHS could consider capping out-of-pocket
costs, or sharing some of the savings from increased rebates
with beneficiaries. As it implements this proposal, HHS
should ensure that the proposed reforms benefit both
patients and payers.
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Invited Commentary
Managing the Cost ofMedicare Part B Drugs
Implications for the Program and Beneficiaries
Francis J. Crosson, MD; Jon B. Christianson, PhD
In this issue of JAMA Internal Medicine, Hwang et al1 assess
the costs to beneficiaries of implementing a draft proposal by
the Department of Health and Human Services (HHS)2 to re-
duceMedicare Part B costs. The plan wouldmove certain ex-
pensive administered drugs
from coverage under Medi-
care Part B to coverage under
Medicare Part D. Medicare
Part B covers drugs that are
administered by infusion or
injection in physician offices or hospital outpatient depart-
ments; Part D covers outpatient prescription drugs.
Based onMedicare claims data and information from the
annual reports of the boards of trustees of theMedicare trust
funds, the Medicare Payment Advisory Commission (Med-
PAC), on which we serve as Chairman (F.J.C.) and Vice-
Chairman (J.B.C.), estimates that the Medicare program and
its beneficiaries spent about $29.1 billion on Part B drugs in
2016, a cumulative increaseof about35%from2013, andabout
$109.1 billion on Part D drugs in 2016, a cumulative increase
of 26% from 2013.3
The intention is to reduce the cost of Part B drugs through
thenegotiationandutilizationmanagementprocessesofPartD
plans. These processes are not currently allowed under Part B.
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